Xtandi (enzalutamide capsule)

.@neerajaiims, of @huntsmancancer, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC. #pcsm https://t.co/xbusmBgW8j (@OncLive)

For patients with HRR gene–mutated mCRPC, additional data supporting the use of the combination of the PARP inhibitor talazoparib with enzalutamide is a welcome signal in the field. @neerajaiims @huntsmancancer #pcsm https://t.co/QMXZaAaaoU (@OncLive)

Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO23 #pcsm https://t.co/IIAaAi2fho (@OncLive)

The addition of Talazoparib(PARPi) to enzalutamide in CRPC has most marked effects in BRCA+ve tumors. Effects in the remaining HRR population are marginal. This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ACScancerchat (@tompowles1)

Agree! In the context of the addition of Talazoparib (PARPi) to enzalutamide in castration-resistant prostate cancer (CRPC), it appears that the most significant effects are observed in tumors that are BRCA positive. However, the effects in the remaining population with… https://t.co/j3Kyx4NTSd (@nataliagandur)

Here, @DrChoueiri MD, joins the @OncBrothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied #talazoparib plus #enzalutamide in first-line #mCRPC. #pcsm | @DanaFarber https://t.co/7zhmpcYZkN (@TargetedOnc)

#DEAR Comparative real-world evidence on darolutamide, enzalutamide, and apalutamide for patients with #nmCRPC in the #UnitedStates. Neal Shore, MD, FRCS @AtlanticUrology and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/XK2NvCkQsU (@urotoday)

Dr. Cora Sternberg (@cnsternberg) sat down with @urotoday to discuss the TALAPRO-2 #ClinicalTrial evaluating talazoparib and enzalutamide for metastatic castration-resistant #ProstateCancer. Results from this study recently led to approval by the @US_FDA: https://t.co/WElMYP2tba (@WCMGUcancer)

#EMBARK trial shows promising results for high-risk #ProstateCancer treatment, enzalutamide's impact on MFS. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss on UroToday > https://t.co/LRUuRj9j8s #AUA23 @AstellasUS @pfizer (@urotoday)

Join @CaPsurvivorship @DanaFarber & @alaccetti @MSKCancerCenter as they discuss the promising data on the combination of enzalutamide with EPI-7386 in #mCRPC pts and this new approach to disrupting the androgen receptor signaling pathway > https://t.co/gOUyvJjXUG @EssaPharma (@urotoday)

🧐Number Needed to #Treat and to #Harm analyses to #compare outcomes in castration-sensitive #prostatecancer patients treated w/ #apalutamide or #enzalutamide ➡️ including data from ARCHES, ENZAMET and TITAN phase 3⃣ trials 🔗https://t.co/6D7ZJsYVLE #TJ🔖 @nataliagandur (@TumoriJ)

The efficacy of enzalutamide + androgen deprivation therapy in oligometastatic hormone-sensitive #ProstateCancer: a post hoc analysis of #ARCHES. #BeyondTheAbstract with @AarmstrongDuke @DukeCancer and @AzadOncology @PeterMacCC on UroToday > https://t.co/8ou1jaeAic @EUplatinum (@urotoday)

From @gr8straj , @EliotBlatt & co-workers: Identification of the central role of #antioxidant programs in enzalutamide-resistant #ProstateCancer 🔬https://t.co/5i0Bv2FXmv (@oncogenejournal)

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC https://t.co/tZeYsWh070 a través de @onclive (@urogomez_)

FDA Approves #Talazoparib Plus #Enzalutamide for HRR Gene–Altered #mCRPC https://t.co/5FyjMzzPcY via @onclive (@a_nourallah)

Our paper identifying that antioxidant programs are essential for enzalutamide-resistant prostate cancer is online now. Go check it out! @gr8straj @RJDLab @Ram_Mani_PhD @jodebon @oncogenejournal https://t.co/hXGLic1xOX (@EliotBlatt)

So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC - @AzadOncology #drugs #Enzalutamide #Talazoparib #usfda #cancer #oncology #oncodaily https://t.co/0JiaY9mS8d (@oncodaily)

@US_FDA approves Talazoparib (Talzenna) + Enzalutamide for mCRPC #prostatecancer with HRR mutations! We are back to precision oncology 👏@neerajaiims @OncoAlert @PCFnews @urotoday @Uroweb @EfstathiouEleni @onkowissen @PfizerOncMed @Uromigos @DrYukselUrun https://t.co/1ociZHTVVe (@amerseburger)

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC https://t.co/8XMEegAIzx via @onclive (@DrBonillaOnc)

Congrats @neerajaiims and team on this new approval of talazoparib-enzalutamide for mCRPC patients with HRR mutations! @NeliMUlrich @Huntsman_GU @PCFnews @charlesryanmd @AzadOncology (@shilpaonc)

Wonderful to see this approval arrive not long after @neerajaiims @huntsmancancer's stellar presentation at @ASCO #GU23 & follow-up paper in @TheLancet! #TALAPRO2 offers a new std of care (#talazoparib w #enzalutamide) for metastatic castration-resistant #prostatecancer with HRR… https://t.co/GtSKG2OD0Y (@montypal)

Wonderful to see this approval arrive not long after @neerajaiims @huntsmancancer's stellar presenation at @ASCO #GU23 & follow-up paper in @TheLancet! #TALAPRO2 offers a new std of care (#talazoparib w #enzalutamide) for metastatic castration-resistant #prostatecancer with HRR… https://t.co/rXw643BBcd (@montypal)

Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer https://t.co/t9O2PrEeg5 @tanyawildes @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Frailty #Efficacy (@JGeriOnc)

🌟The Benefit of the Addition of Talazoparib to Enzalutamide in First Line Treatment for mCRPC #TALAPRO2 by @neerajaiims on @urotoday. 🌟Exciting advancements in #prostatecancer research and potential for improved outcomes! #oncology #medicalresearch https://t.co/kDDUZWla56 (@nataliagandur)

@neerajaiims @huntsmancancer and @CaPsurvivorship @DanaFarber discuss results from the #TALAPRO-2 phase 3 trial, showing a 36% reduction in risk of radiographic progression in patients with #mCRPC treated with talazoparib and enzalutamide. #WatchNow > https://t.co/pe2ho6oXbo (@urotoday)

TALAPRO-2 involving enzalutamide with talazoparib, confirmed statistical benefit for patients with castrate-resistant prostate cancer. This trial was run at TKCC, and we are thrilled with the results. A special thank you to all involved @AnthonyMJoshua https://t.co/oHhxrXMnPa (@kinghorncancer)

Now in @EUplatinum: ➡️ODENZA trial - open-label, x-over study of Darolumatimde vs Enzalutamide ➡️Less fatigue & memory issues with Daro ➡️But no diff in pt preference ➡️ My take: both Daro & Enza excellent options for pts with mCR #prostatecancer (@AzadOncology)

#EMBARK trial shows promising results for high-risk #ProstateCancer treatment, enzalutamide's impact on MFS. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss on UroToday > https://t.co/LRUuRj8LiU #AUA23 @AstellasUS @pfizer (@urotoday)

Join @CaPsurvivorship @DanaFarber & @alaccetti @MSKCancerCenter as they discuss the promising data on the combination of enzalutamide with EPI-7386 in #mCRPC pts and this new approach to disrupting the androgen receptor signaling pathway > https://t.co/gOUyvJjXUG @EssaPharma (@urotoday)

Patients with nmCRPC who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide. @CaPsurvivorship @DanaFarber https://t.co/L1S1M3wm3G (@OncLive)

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment https://t.co/GqOmOEvo3h #pcsm #prostatecancer #oncology #ASCO23 @CaPSurvivorship @DanaFarber @GustaveRoussy (@ASCOPost)

Concurrent chemo-hormonal therapy of enzalutamide and cabazitaxel in patients with #mCRPC: final analysis of ORR, rPFS, and OS. Presentation by @sokolova_md @OHSUKnight. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/4sC64atkDl @ASCO (@urotoday)

#ASCO23: TALAPRO-2: Talazoparib + enzalutamide in the first-line setting significantly reduces the risk of progression or death by 55% among pts w/ HRR–deficient #mCRPC: https://t.co/eHBlENaRWG #ASCODailyNews #GUCSM #pcsm @vanderweelemd (@ASCO)

Talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer #mCRPC: Safety analyses from the randomized, placebo-controlled, phase 3 #TALAPRO2 study. Presented by @AzadOncology @PeterMacCC. #ASCO23 written coverage by @tchandra_uromd > https://t.co/mam7BYi0vZ (@urotoday)

Great data showing no adverse events with dose escalation of #Enzalutamide (120) + #Relacorilant (150) treatment in metastatic castration resistant #prostatecancer patients. @ASCO #ASCO23 @UCCancerCenter @RandySweisMD (@UCCancerCenter)

The one and only @fizazikarim presents the results of #TALAPRO2 Results in cohort 1 reported by @neerajaiims #ASCOGU23 and out @TheLancet ! In cohort 2: talazoparib + enzalutamide ⬆️rPFS and a trend towards ⬆️OS (immature) in #mCRPC with #HRRm (BRCA++) (@DrChoueiri)

Darolutamide associated with lower risk of treatment discontinuation, longer time to progression to mCRPC and adverse events compared with enzalutamide and apalutamide in real-world cohort with nonmetastatic CRPC from urology practices -@CaPsurvivorship #asco23 (@LoebStacy)

#DEAR Comparative real-world evidence on darolutamide, enzalutamide, and apalutamide for patients with #nmCRPC in the #UnitedStates. Presented by @CaPsurvivorship @DanaFarber. #ASCO23 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/knX2T3V6Kd @ASCO (@urotoday)

#ASCO23 | Hall A | Sat 8am CT A Phase 2, Randomized, Open-label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients With Hormone-naive Prostate Cancer: ARAMON Study @xingao04 https://t.co/I4j2RKV3WG #MGCCatASCO23 (@MGHCancerCenter)

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES - Beyond the Abstract A pleasure to write this with ⁦@AarmstrongDuke⁩ https://t.co/4pgJynP89T (@AzadOncology)

Abs#5004 #ASCO23 @ASCO: Results from HRR pts in TALAPRO-2 (1L mCRPC Enzalutamide +/-Talazoparib) show sig. ⬆️ rPFS (HR 0.45; P< 0.001). Benefit in BRCA 1/2 (HR 0.20; P< 0.001) > non-BRCA1/2 (HR 0.68; P=0.06). Immature OS data but favouring Talazoparib (HR 0.69; P = 0.07). (@AzadOncology)

Ab#5004 #ASCO23 @ASCO : The results of Ph3 TALAPRO-2 of talazoparib + enzalutamide vs placebo + enzalutamide in HRR positive pts in 1st line mCRPC #prostatecancer➡️rPFS HR 0.20 (95% CI, 0.11–0.36; P < 0.001) for the BRCA1/2 subgroup; HR 0.68 (95% CI, 0.46–1.02; P = 0.06) in… https://t.co/R0N0OVaCkR (@neerajaiims)